glp-1 agonists receptor show promise in treating substance use disorders PDB-101: Molecule of the Month:
Description
At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk
Individual results may vary
Think of your gut like a garden
See how GLP-1s are reshaping diabetes & obesity care.
New research suggests that switching to a maintenance dose of GLP-1 medication could help lock in weight loss.
Rare disorders and disease progression were not examined
